It was a randomized double blind phase III study on NSCLC patients without EGFR, ALK, and ROS mutations, comparing cemiplimab in combination with chemotherapy against chemotherapy alone; the OS was 21.9 and 13.8 months respectively, indicating a clinically significant difference [103]. Here, EGFR is linked to non-small cell lung carcinoma.